Can a heart pill protect the liver? new study tests irbesartan against hepatitis c scarring
NCT ID NCT00265642
First seen Apr 17, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study tested whether irbesartan, a blood pressure medication, can slow the progression of liver fibrosis (scarring) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. 166 participants took either irbesartan or a placebo daily for two years. The main goal was to measure changes in liver scarring using biopsies and blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Angers, Service d'hépato-gastroentérologie
Angers, 49933 cedex 09, France
Conditions
Explore the condition pages connected to this study.